CClinicalTrials.gg
CompletedNCT01346280Updated Dec 17, 2019

Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs

An observational study in Non-Small Cell Lung Cancer (Stage III), Colon Cancer (Stage II &Amp; III) and Rectal Cancer (Stage III), sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by National Cancer Institute (NCI) · Observational

Study type
Observational
Time perspective
Other
Enrollment
1,079
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Background:

-Coordinated cancer care provided by doctors, nurses, social workers, and other care providers is believed to improve patient and physician satisfaction and patient evaluation for enrollment in clinical trials. But no research has been done to show that this approach improves patient experiences and outcomes. Researchers want to study this model to better understand how it can improve cancer treatment and patient outcomes.

Objectives:

  • To assess the relationship between coordinated care and cancer treatment processes and outcomes.

Eligibility:

  • Individuals who are at least 18 years of age. Those who take part must have been diagnosed with colon, rectal, or non-small-cell lung cancer. They also must be receiving or have been treated at one of the 16 NCI Community Cancer Center program sites.

Design:

  • Researchers will collect medical records data from participants.
  • Participants will complete a questionnaire about 8 weeks after the end of all planned cancer treatment. They will be asked questions about their experience with coordinated cancer care. They will also be asked for any comments or concerns they had during and after treatment.
  • No treatment or additional tests will be provided as part of this protocol.
Read the detailed description

There is little evidence regarding the effect of multidisciplinary care (MDC) on health outcomes across various cancer sites, including colon, rectal, and lung cancer. The current study addresses this gap by providing preliminary data regarding the relationship between MDC and selected processes and outcomes of care in NCCCP pilot sites. The long-term goal of this preliminary study is to generate effect sizes, establish feasibility, and build infrastructure to support the development of a larger more definitive study of MDC outcomes. The key aim of this pilot study is to determine the relationship between specific MDC assessment areas identified by a pre-existing MDC assessment tool (http://ncccp .cancer.gov /NCCCPMDC- Matrix- Tool. pdf ): case planning, physician engagement, coordination of care, infrastructure, financial, clinical trials and medical records, and each of the following outcomes [0] and processes [P]: 1) time to receipt of initial therapy[P]; 2) receipt of multi-modality therapy[O]; 3) evaluation for enrollment in a clinical trial[P]; 4) patient experience[O]; 5) adherence to NCCN treatment guidelines[P]; and 6) all-cause survival[O]. The study focuses on adult patients with an incident diagnosis of Stage III colon cancer, Stage II or III rectal cancer, or Stage III non-small cell lung cancer.

We will quantify the relationship between MDC, various care processes and outcomes across 16 participating NCCCP sites, testing the hypothesis that increasing levels of MDC identified by the MDC tool are associated with improvement in care quality and a survival advantage.

Significant progress has been achieved in the past year establishing the necessary

processes for conducting the research study and the deliverables associated with the study. In terms of process outcomes, we can report the following:

  1. Institutional Review Board approval for the multidisciplinary care study at all 16

    sites;

  2. The development of a Standard Operating Procedures manual for use by the 16 sites;
  3. The development of a data collection form (Site Data Collection Tool) to be used for

    collecting information that is not available via the pre-existing web-based data

    collection system that is in place at the 16 sites;

  4. The development of a data collection form to be used for documenting the facility s

    annual scores using the Multidisciplinary Care Assessment tool.

  5. The development of a flowchart for use in operationalizing the measurement of

    NCCN guideline adherence for patients with Stage III non small cell lung cancer;

  6. The development of a Frequently Asked Questions document to assist with

    addressing questions in real time;

  7. Multiple training sessions/webinars have been held for the participating sites.
  8. Monthly conference call with the research team and representatives from all

participating sites.

02

Conditions studied

  • Non-Small Cell Lung Cancer (Stage III)
  • Colon Cancer (Stage II &Amp; III)
  • Rectal Cancer (Stage III)

Keywords

  • Adherence to Evidence-Based Guidelines
  • Multidisciplinary Care
  • Patient Experiences
  • Quality of Care Outcomes
03

In context

Carcinoma, Non-Small-Cell Lung

6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,630 are open to participants now.

This study's enrollment of 1,079 is above the median of 161 across 948 observational studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,506 studies on the registry; 334 are open to participants now.

Of its 402 completed or terminated interventional studies of FDA-regulated products, 365 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • INCLUSION CRITERIA:

Stage III colon cancer, Stage II or III rectal cancer or Stage III lung cancer. Additional inclusion criteria: Age: equal to or greater than 18 at time of diagnosis; English speaking (native or non-native); First or only cancer diagnosis; All or part of first course of treatment was performed at the reporting facility.

05

Study design

Time perspective
Other
Enrollment
1,079 participants (actual)
06

Study locations

1 site
  • National Cancer Institute (NCI), 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
07

References and documents

Publications

  • Freeman RK, Van Woerkom JM, Vyverberg A, Ascioti AJ. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer. Eur J Cardiothorac Surg. 2010 Jul;38(1):1-5. doi: 10.1016/j.ejcts.2010.01.051. Epub 2010 Mar 4. PubMed 20206544 ↗
  • Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr. 2010;2010(40):72-80. doi: 10.1093/jncimonographs/lgq010. PubMed 20386055 ↗
  • Sidhom MA, Poulsen MG. Multidisciplinary care in oncology: medicolegal implications of group decisions. Lancet Oncol. 2006 Nov;7(11):951-4. doi: 10.1016/S1470-2045(06)70942-1. PubMed 17081921 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01346280
Lead sponsor
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
May 2, 2011
Start date
Apr 16, 2011
Completion
Oct 5, 2015
Last update
Dec 17, 2019

Study contacts

Kathleen Castro, R.N.
principal investigator · National Cancer Institute (NCI)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion